The Role of Dendritic Cells in Hepatitis C Infection

Chronic Hepatitis C Infection Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00723242
• Other study ID #: unknown
• Status: Completed
• Phase: N/A
• First received: July 24, 2008
• Last updated: July 24, 2008
• Start date: April 2002
• Est. completion date: December 2004

Study information

• Verified date: July 2008
• Source: University College, London
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: National Health Service
• Study type: Interventional

Clinical Trial Summary

The role of the dendritic cells, the most potent antigen presenting cells, in the establishment of chronic hepatitis C is not established. The study aims to define whether the dendritic cells are affected by the hepatitis C virus and whether that bears an impact on the antiviral immune response they generate. The hypothesis is explored by investigating a group of patients prior to and after the initiation of standard treatment for hepatitis C with pegylated Interferon and Ribavirin.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: December 2004
• Est. primary completion date: December 2004
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• anti-HCV positive

• HCV RNA positive

Exclusion Criteria:

• contraindications for antiviral treatment

• concurrent chronic viral infections

Study Design

Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Chronic Hepatitis C Infection
• Hepatitis
• Hepatitis C
• Hepatitis C, Chronic
• Hepatitis, Chronic

Intervention

Drug:
• Viraferon-peg and Rebetol

Locations

Country	Name	City	State
United Kingdom	University College Hospital	London

Sponsors (2)

Lead Sponsor	Collaborator
University College, London	Schering-Plough

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Basic science research (immunology of hepatitis C)in hepatitis c patients receiving established, standard antiviral treatment (pegylated Interferon+Ribavirin)			No